AXSM(Axsome Therapeutics, Inc.) · 财务报表

AXSM(Axsome Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$50.04M$270.60M$385.69M$638.50M
毛利润$44.84M———
营业利润−$179.80M−$231.82M−$280.56M−$166.76M
净利润−$187.13M−$239.24M−$287.22M−$183.17M
经营现金流−$116.51M−$145.08M−$128.41M−$93.41M
自由现金流−$117.21M−$145.66M−$128.68M−$93.89M
摊薄每股收益$-4.60$-5.27$-5.99$-3.68

Axsome Therapeutics, Inc. AXSM